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Abstract
Background: Collision tumors of the thyroid are rare, with occasional reports dealing with their
genetic analysis.
Case presentation: A 59 year old lady presented with a neck mass, associated with hoarseness
of voice of 5 years duration. Radiological examination revealed nodular masses in the left lobe of
her thyroid, along with one in the isthmus, extending into the right lobe and associated with
enlarged neck nodes. FNAC from the left thyroid showed features of medullary carcinoma. On
total thyroidectomy, 2 distinct tumor nodules were identified in the left lobe with another in the
isthmus, showing features of medullary carcinoma (MTC), papillary carcinoma and follicular variant
of papillary carcinoma, respectively, accompanied with nodal metastasis. Subsequently, she
underwent radioablation. RET gene analysis of the patient, her 2 daughters and a grandson revealed
a unique G691S polymorphism on Exon 11.
Conclusion: This unique case of a collision tumor of thyroid, including component of an MTC
deals with the value of RET gene analysis and therapeutic implications in the index case and in family
members.
Introduction
The two discrete functional cellular components of a thy-
roid gland i.e. follicular epithelium and parafollicular C
cells give rise to distinct neoplasms i.e. differentiated fol-
licular or papillary thyroid carcinoma (PTC), from the
former type and a medullary thyroid carcinoma (MTC)
from the latter type of cells [1]. A MTC manifests either in
sporadic or in hereditary form; the latter occurs as an iso-
lated familial MTC or as a part of a multiple endocrine
neoplasia (MEN I and II) syndrome [2]. Varying admix-
ture of the two cell types, designated as a mixed tumor, is
uncommon, but reported in a substantial number of cases
[3-6]. This entity has also been recognized in the WHO
classification of thyroid tumors1. However, occurrence of
distinct tumor nodules, without an intermingling of the
cell types, known as a 'collision' or a 'concurrent' thyroid
tumor that represents < 1% of all thyroid malignancies,
has been reported as few case reports [7-10]. Further, only
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occasional case reports have dealt with the genetic analy-
sis in a collision thyroid tumor [11]. While activating
germline point mutations in the RET gene are responsible
for MTCs (associated with MEN 2), RET rearrangements
in form of fusion of the RET cytoplasmic kinase domain
to 5-ter of heterologous genes, generating the chimeric
RET/PTC oncogenes, are linked to PTCs [12]. Herein, we
describe a case of a collision tumor of the thyroid with
metastatic lymph nodes. On genetic analysis, the patient
revealed a unique G691S polymorphism on the exon11 of
the RET Proto-oncogene that was also identified in both
her daughters and a grandson. This case is discussed with
its possible genetic and therapeutic implications.
Case presentation
A 59 years old lady presented with the complaints of a
slowly increasing thyroid swelling, since 5 years, accom-
panied with hoarseness of voice; dry cough for two years
and an increasing pain since 6 months. She denied any
symptoms of hypo- or hyperthyroidism; dysphagia,
abdominal pain, irradiation in the head and neck region
or any family history of thyroid cancer.
On examination, a large, firm to hard, non tender thyroid
mass measuring 6 × 5 cms was noted in the infrahyoid
region of the neck, more so towards the left side, associ-
ated with an enlarged left level II cervical lymph node that
measured 3 × 3 cms. On laryngoscopy (Hopkin's), both
the vocal cords were normal in mobility. However, the
mass was presumed to be involving the strap muscles.
There were no manifestations of MEN syndrome. A clini-
cal stage T4a, N1, M0 for thyroid cancer was assigned. Sub-
sequently, she underwent a fine needle aspiration
cytology (FNAC) on which a diagnosis of medullary carci-
noma was rendered. She underwent a total thyroidectomy
with bilateral complete cervical nodal clearance. A final
histopathological diagnosis of a 'collision' tumor of the
thyroid, including components of MTC and PTC, occur-
ring as discrete tumor nodules in the left thyroid, along
with a FVPTC in the isthmic tumor nodule, was offered. In
addition, the left cervical nodes revealed nodal metastasis
of MTC.
Radiological findings
Ultrasonographic (USG) Neck findings
An enlarged heterogenous mass was noted in left lobe of
the thyroid, measuring 6.8 × 4.4 × 3.5 cms, along with
another heterogeneous hypoechoic nodule in the mid
and inferior pole of the left thyroid lobe, measuring 2.6 ×
2.5 × 2.1 cms. In addition, there was another hypoechoic
nodule in the isthmus measuring 2.5 × 1.8 cms, extending
into the right lobe and revealing cystic areas. Enlarged
level II and level IV nodes were also noted. 'Specks' of cal-
cification were identified in the thyroid mass as well as in
the lymph nodes. (Figure 1A). The parathyroid glands
were normal. USG findings of abdomen did not reveal
any specific abnormality.
Computed Tomography (CT) scan findings
An enlarged heterogeneous mass was noted in the left
lobe of the thyroid, pushing the ipsilateral strap muscles
and trachea and showing areas of calcification and 'necro-
sis'. The ipsilateral major neck vessels were also displaced
posteriorly, along with multiple enlarged nodes at levels II
and III. CT findings of thorax and abdomen were within
normal limits (Figure 1B).
Methods
The resected tumor was processed for paraffin sections.
Five micron thick sections were stained with hematoxylin
and eosin (H& E), alkaline Congo red stains and further
subjected to immunohistochemistry (IHC), using strepta-
vidin-biotin method. The various antibody markers per-
formed were calcitonin (polyclonal, 1:50 dilution, Dako-
CAL-3F5), thyroglobulin (monoclonal, 1:50 dilution,
Dako), carcino embryogenic antigen (CEA, polyclonal,
1:600 dilution, Dako) and chromogranin (polyclonal,
1:100 dilution, Dako).
Further, the patients' blood was submitted for genetic test-
ing for RET gene analysis. DNA was isolated using stand-
ard protocol [13]. Tissue DNA analysis was not
performed. Direct sequencing of PCR products was used
A. USG findings neck Figure 1
A. USG findings neck. An enlarged heterogenous mass in the 
left lobe of the thyroid along with another cystic hypoechoic 
nodule in the isthmus extending into the right lobe (thin 
arrow). B. CT Scan findings. an enlarged heterogeneous mass 
with areas of calcification and 'necrosis' in the left lobe of the 
thyroid (thick arrow) along with another discrete cystic nod-
ule in the isthmus (thin arrow). C. Gross findings. A solid, 
fleshy, grey white tumor in the left lobe of the thyroid. D. 
Isthmic nodule exhibiting multiple cystic areas.Diagnostic Pathology 2007, 2:39 http://www.diagnosticpathology.org/content/2/1/39
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to detect the mutations in the various exons, namely 10,
11, 13, 14 and 16 of the RET oncogene. Rest of her family
members, including her children were counseled, who
also underwent the similar genetic analysis.
Amplification and sequencing analysis
DNA extraction was done using Qiagen column and PCR
protocol. Genomic DNA was amplified by PCR using
primers described previously [11]. The PCR product was
directly sequenced using Big Dye Terminator v3.1 cycle
sequencing kit, nucleotide sequencing using AB13100
Genetic Analyzer. The sequences were analyzed with refer-
ence sequence using ClustaIW software and the polymor-
phisms were identified.
Results
Biochemical findings
Preoperatively, the serum calcitonin levels were found to
be high i.e. 32,150 pg/ml. The serum levels for total and
ionic calcium were low i.e. 6.4 mg/dl (Normal: 8.6–10
mg/dl) and 3 mg/dl (Normal: 4.5–5.3 mg/dl), respec-
tively. Serum T3, T4, thyroid stimulating hormone (TSH)
and parathyroid hormone (PTH) levels were within nor-
mal limits. Total and fasting blood sugar levels were nor-
mal. The 24-hour urine levels for vanyl-mandelic acid
(VMA) were 2 mg/day (Normal: 15 mg/day) and for
metanephrines were 91.8 µg/day (Normal: 0–350 µg/
day), both within normal limits.
Pathological findings
Grossly, a specimen of total thyroidectomy was received
that measured 11 × 10 × 4 cms and consisted of right lobe,
measuring 7.3 × 3 × 2.5 cms; isthmus measuring 4 × 3.5 ×
2 cms and left lobe, measuring 11 × 6 × 5 cms. Externally,
the capsule was intact. On serial sectioning, a solid, fleshy,
grey white tumor measuring 8 × 3.5 × 2.5 cms was seen
involving the left lobe of the thyroid and focally abutting
the thyroid capsule. A separate, well-defined, grey-white
nodule measuring 2.5 × 2.1 × 1.8 cms was also noted at
the apex of the same lobe. Another ill defined nodule in
close proximity to the larger nodule was seen measuring
1.5 × 1.2 × 0.8 cms and involving the isthmus and adja-
cent right lobe of the thyroid. This nodule exhibited mul-
tiple cystic areas containing blood and colloid with focal
papillary excrescences. Extrathyroid extension was noted
(Figure 1C, Figure 1D).
The left and right central compartment nodes, right level
IIA, IIB, III and IV nodes and the left level IIA, III, IV and
V nodes were also sampled separately, the largest measur-
ing 3.5 × 2.3 × 1.8 cms.
Microscopic findings
FNAC smears were hypercellular with oval to polygonal
cells, singly dispersed, including binucleate and plasma-
cytoid forms. Cells exhibited moderate amount of granu-
lar cytoplasm and 'salt and pepper' like nuclear
chromatin. Few tumor giant cell forms were also noted. A
diagnosis of a medullary carcinoma thyroid was rendered
(Figure 2A).
Histopathological findings
H& E stained sections from the left thyroid nodule
showed 2 tumor nodules separated by a sleeve of normal
thyroid parenchyma. The larger nodule showed features
of a MTC, including sheets and nests of cells, embedded
in a hyaline matrix, with plasmacytoid shape and neu-
roendocrine features and the other nodule, showing fea-
tures of a differentiated papillary carcinoma with tumor
cells, exhibiting 'optically clear' nuclei with grooves and
intranuclear inclusions. Sections from the isthmic nodule
showed features of follicular variant of papillary carci-
noma (FVPTC). Extrathyroid extension was seen. Out of a
total of 44 sampled nodes, 4 showed metastasis of MTC,
two from the left central compartment and one, each,
from the right central compartment and the left level IIB
nodes. Perinodal extension was noted (Figure 2B, C, D,
E).
Microscopic findings Figure 2
Microscopic findings. A. Cellular smears from left lobe show-
ing tumor cells with eccentric nuclei, mostly dispersed singly 
with hyperchromatic nuclei. Giemsa staining 400 ×. B. Sec-
tion from the left lobe nodule showing sheets of plasmacy-
toid cells (arrow) with 'salt and pepper-like' chromatin 
amidst amyloid (Am) stroma. H & E 200 ×. C. Section from 
second nodule showing nuclear features of PTC, including 
nuclear grooves and intranuclear inclusions (arrow). H & E 
400 ×. D. Isthmic nodule showing features of FVPTC. H & E 
200 ×. E. Nodal deposits from MTC. H & E 200 ×. F. Apple 
green birefringence of amyloid stroma. Alkaline Congo Red 
200 ×. G. Positive thyroglobulin expression in PTC. DAB 400 
×. H. Calcitonin positivity in MTC. DAB × 200. I. Positive 
CEA expression in MTC. DAB × 400.Diagnostic Pathology 2007, 2:39 http://www.diagnosticpathology.org/content/2/1/39
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Alkaline Congo red staining showed 'apple-green' bire-
fringence of the hyalinized material, under a polarizing
microscope, thereby confirming the presence of amyloid
stroma, in the areas of MTC (Figure 2F)..
On immunohistochemistry (IHC), calcitonin CEA and
chromogranin were found to be positive in the tumor cells
of medullary carcinoma, while TG was positive in the
tumor cells of PTC and FVPTC (Figure 2G, H, I).
Genetic analysis
The patients' DNA revealed a polymorphism in the heter-
ozygous form in the RET Proto-oncogene at the exon 11
codon 691, resulting in GGT to AGT conversion, substitut-
ing Glycine to Serine (Figure 3A, B). Among her children,
who underwent the similar genetic screening, both her
daughters revealed the similar polymorphism in hetero-
zygous form. However, the daughters' only child was
spared with this mutation. In addition, one of her grand-
son also revealed the same polymorphism in hetero-
zygous form (Figure 4A, B, C, D). Her son escaped the
polymorphism (Figure 5). A follow-up of the patient, her
daughters and grandson was recommended.
Further treatment and follow-up
Subsequent to a total thyroidectomy with bilateral com-
plete cervical nodal clearance, the patient underwent a
diagnostic radioiodine scan with 100 µCurie that showed
an uptake of 4.13%. Hence, a radio ablation with 195
milli Curie was performed after which the patient has
been on a regular follow-up.
Discussion
The occurrence of thyroid carcinomas with varying admix-
tures of MTC and differentiated carcinoma of the follicu-
lar epithelium has generated sufficient interest and
controversy in terms of the histogenesis and appropriate
designation for these tumors. In a comprehensive analy-
A. 2% Agarose gel electrophoresis of the index case Figure 3
A. 2% Agarose gel electrophoresis of the index case. B. Sequencing Electropherogram of the Exon 11.Diagnostic Pathology 2007, 2:39 http://www.diagnosticpathology.org/content/2/1/39
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sis, Guiu [14] has reviewed the available literature in
terms of the histogenesis of a spectrum of such tumors.
The present case of a collision tumor, including a MTC,
PTC and a FVPTC was identified in a lady, who did not
reveal any clinical manifestations an MEN syndrome. His-
tologically, discrete tumor nodules were identified in the
left lobe and isthmus with features of MTC and PTC. Pres-
ence of amyloid stroma with strong calcitonin positivity
confirmed the diagnosis of a MTC, whereas classical
nuclear features with thyroglobulin positivity were help-
ful in confirming a PTC as well as a FVPTC. There was no
intermingling of the two types of tumor cells, barring a
diagnosis of a mixed thyroid carcinoma [3-8]. The lymph
node deposits were of a MTC, unlike a mixed tumor, as
noted earlier [9].
Lately,  RET  (rearrangements in tyrosine kinase) proto-
oncogene has been implicated in the development of
familial and sporadic MTC [15,16]. Several germline
point mutations of this gene have been found to be affect-
ing Exons 10, 11, 13, 14, 15 and 16 that have been linked
with the development of MEN 2 and familial MTC. RET
somatic point mutations and gene deletions have been
identified in 40–50% cases of sporadic MTC [17]. Our
case did not reveal a familial history of MTC. On genetic
analysis, the patient displayed a unique G691S polymor-
phism that has been lately found to be associated with
sporadic MTCs [18,19]. It is noteworthy that the high risk
mutation was absent. It has been proposed that G691S
polymorphisms might be important for its putative role in
the pathogenesis of sporadic MTCs. This has been found
to be associated with C-cell hyperplasia in the pretumor
tissue of the differentiated radiation induced thyroid
tumors [20]. As C-cell hyperplasia is considered as a pre-
neoplastic lesion by some authors, there is a possibility
that the G691S polymorphism induces C-cell hyperplasia.
A. 2% Agarose gel electrophoresis of the daughter of the index case Figure 4
A. 2% Agarose gel electrophoresis of the daughter of the index case. B. Sequencing Electropherogram of the Exon 11 case. C. 
2% Agarose gel electrophoresis of the grandson of the index case. D. Sequencing Electropherogram of the Exon 11.Diagnostic Pathology 2007, 2:39 http://www.diagnosticpathology.org/content/2/1/39
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However, according to Elisei et al [18], it is difficult to
deduce that normal subjects harboring G691S polymor-
phism are at a higher risk of MTC. Nevertheless, in a recent
study by Robledo et al [19], it has been clearly suggested
that the presence of G91S/S904S polymorphisms of the
RET is related to the early appearance of symptoms in
MEN 2A patients, and therefore, these polymorphisms
could be considered as genetic modifiers. A G691S poly-
morphism might be included as a low penetrance gene
that might be associated with a small to moderate
increased risk for the development of a MTC. Although
our index case was a lady, both her daughters and a grand-
son, displaying the similar polymorphism could be at risk
for development of an early MEN2A syndrome.
The exact mechanism by which these polymorphisms
affect the age of onset for MTC is unclear. It has been
explained that the G691S variant occurs in the cytoplas-
mic tail of the RET amidst transmembrane region and the
first tyrosine kinase domain close to the residue Y687 that
was found phosphorylated in all MEN 2A cases, along
with few cases of MEN 2B. Even though G691S is not con-
sidered as an oncogenic mutation, its functional role has
been hypothesized. Higher levels of this polymorphism
have been noted in sporadic cases of MTC vs normal sub-
jects, thereby suggesting its role as a low penetrance gene.
It has also been postulated that such variants are relatively
common in the population may confer a much higher
attributable risk in the general population than mutations
in high penetrance cancer susceptibility genes [19].
Apart from a MTC, the present case also had discrete
tumor nodules of PTC and FVPTC. In a literature review,
Rossi et al [21] identified 21 such cases, including 3 cases
from their own study that in addition, included genetic
analysis. They noted C634A substitution in the exon 11 of
the RET gene in the MTC component, while V600G BRAF
mutation in the PTC tissues, thereby suggesting the possi-
bility of discrete mutations in both the tumors. In the
present case BRAF mutation analysis was not carried out.
Similar to ours, in their unique case of a collision tumor,
Papi et al [11] identified a mutation on the RET gene.
However, the affected Exon and codon was Exon 14
(codon 804). Recently, Melillo et al [22], while analyzing
the transforming activity of RET mutations in PC CI3 fol-
licular cells, in case of a family with affected siblings
showing a collision tumor, postulated that RET point
mutants behave as conditional oncogenes, able to predis-
pose to PTC only under specific circumstances, such as,
high level expression of the mutated allele in follicular
cells. However, the present case displayed occurrence of a
low penetrance gene. It is possible that low penetrance
genes, acting over a long time, provide a 'fertile soil' for
further mutations or differential expression, leading to
development of collision tumors. It is suggested that
occurrence of RET polymorphisms in such cases might
validate the proposed hypotheses of 'field-effect' in cases
of MTC, as well as about C-cells differentiating into follic-
ular cells [13].
Therapeutically, it is important to identify whether cases
of collision tumors should be given radioactive 131Iodine.
In the present case, in view of an increased radioactive
iodine uptake, post surgery, the patient was subjected to
radio ablation. Identification of mutations or polymor-
phisms as G691S in the progeny of this case opens the
possibility of discussing the screening in the subsequent
family members. In such cases, calcitonin (CT) levels,
especially post calcium or pentagastrin infusion have
been found to be useful to decide upon therapeutic inter-
ventions as the polymorphism in itself is not like a high
risk mutation. While basal calcitonin level is < 30 pg/ml,
levels between 30 to100 indicate C-cell hyperplasia and
above 100 pg/ml indicate presence of a MTC. CT levels
between 30 to100 necessitate further investigations
including USG/CT scan examination for the detection of
thyroid nodule [23]. Presently, the patient's daughters
have normal calcitonin levels and unremarkable thyroid.
In view of unremarkable thyroids and normal calcitonin
levels, therapeutic intervention has not been carried out in
the patient's progeny. Nonetheless, they are on regular fol-
low-up.
Even though screening modalities and therapeutic impli-
cations are known in cases of familial MTC, the same have
not been established in sporadic MTCs. The present case
of a collision tumor, displaying a unique G691 polymor-
Pedigree of the family with the index case (arrow) Figure 5
Pedigree of the family with the index case (arrow). Affected 
individuals (shaded dark) were heterozygous for the poly-
morphism.Diagnostic Pathology 2007, 2:39 http://www.diagnosticpathology.org/content/2/1/39
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phism, is suggestive of additional genetic modifiers of RET
gene mutations in cases of sporadic medullary carcinoma
thyroid. To our knowledge, such a polypmorphism has
not been documented in any case of a collision thyroid
tumor. Identification of such low penetrance genes pro-
vides a scope for genetic screening in cases of pure MTC,
mixed or collision tumors. Documentation of more such
cases, with a follow up is necessary to lay management
guidelines for family members detected with the similar
polymorphism, as of the index case.
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